[6-K] Oncolytics Biotech, Inc. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

AirJoule Technologies Corp. (AIRJ) – Form 4 insider transaction

Director Denise Marie Brucia Sterling was granted 25,487 restricted stock units (RSUs) on 07 / 07 / 2025 (Transaction Code “A”). Each RSU represents the right to receive one share of Class A common stock at no exercise cost. The RSUs will vest on the earlier of 07 / 07 / 2026 or the company’s next annual shareholders’ meeting. Following the award, the director beneficially owns 25,487 derivative securities; no common shares were bought or sold.

This filing reflects a routine equity-compensation grant. While it introduces a small potential for dilution when the units convert, it strengthens alignment between board incentives and shareholder interests. No other insider activity or financial data were disclosed.

Positive

• Enhanced alignment: RSU grant links director compensation to AIRJ share performance, potentially benefiting shareholder interests.

Negative

• Minor potential dilution: Conversion of 25,487 RSUs will incrementally increase shares outstanding upon vesting.

Insights

Securities Analyst

TL;DR: Routine RSU grant; negligible size, neutral valuation impact.

The 25,487-unit award represents a modest addition to AirJoule’s fully diluted share count and involves no cash proceeds. RSUs vest within one year, so future dilution is limited and predictable. Such grants are standard for director compensation, suggesting no insider sentiment shift or liquidity need. From a valuation standpoint, the impact is immaterial and does not alter the equity story.

Corporate Governance Expert

TL;DR: Grant improves pay-for-performance alignment; governance implications neutral.

Equity-based compensation ties director wealth directly to stock performance, promoting shareholder alignment. The one-year vesting schedule is relatively short, but still encourages near-term stewardship. No red flags—no accelerated vesting, preferential pricing, or unusual volume. Overall, governance standards appear intact, and the filing is non-impactful to control dynamics.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the month of July 2025

Commission File Number 001-38512

Oncolytics Biotech Inc.

(Translation of registrant’s name into English)

Suite 804, 322 11th Avenue SW

Calgary, Alberta, Canada T2R 0C5

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F   þ Form 40-F   o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   o

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   o

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

EXHIBIT NUMBER						DESCRIPTION
99.1						Information Circular
99.2						Form of proxy

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Oncolytics Biotech Inc. (Registrant)

Date: July 8, 2025

By:

/s/  Kirk Look Kirk Look Chief Financial Officer

FAQ

What insider transaction did AIRJ report in this Form 4?

AIRJ disclosed a grant of 25,487 restricted stock units to director Denise Marie Brucia Sterling.

How many RSUs were granted to Denise Marie Brucia Sterling?

She received 25,487 RSUs on 07/07/2025.

When do the 25,487 RSUs granted on 07/07/2025 vest?

They vest on the earlier of July 7, 2026 or the next annual shareholders’ meeting.

Did the insider sell any AIRJ shares in this filing?

No. The filing reports only an RSU grant; no shares were sold or disposed.

What is the potential share dilution from the RSU grant?

If all RSUs convert, up to 25,487 new common shares would be issued, a small addition to AIRJ’s float.

Is cash required to exercise the RSUs?

No. The RSUs convert to common shares at an exercise price of $0 upon vesting.